Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Short term Debt (2016 - 2025)

Achieve Life Sciences (ACHV) has disclosed Short term Debt for 5 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.7 million for FY2025, N/A changed from the prior year.
  • Short term Debt for Q4 2025 was $3.7 million at Achieve Life Sciences, up from $1.2 million in the prior quarter.
  • The five-year high for Short term Debt was $17.1 million in Q1 2024, with the low at $528000.0 in Q4 2023.
  • Average Short term Debt over 4 years is $7.4 million, with a median of $3.7 million recorded in 2025.
  • The sharpest move saw Short term Debt crashed 96.71% in 2023, then grew 4.7% in 2024.
  • Achieve Life Sciences' Short term Debt stood at $16.1 million in 2022, then crashed by 96.71% to $528000.0 in 2023, then surged by 1567.42% to $8.8 million in 2024, then crashed by 57.93% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ACHV's Short term Debt are $3.7 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).